PMC:7361216 / 2277-3084 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T25","span":{"begin":108,"end":111},"obj":"Body_part"},{"id":"T26","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T27","span":{"begin":371,"end":383},"obj":"Body_part"},{"id":"T28","span":{"begin":401,"end":414},"obj":"Body_part"},{"id":"T29","span":{"begin":430,"end":438},"obj":"Body_part"},{"id":"T30","span":{"begin":485,"end":493},"obj":"Body_part"},{"id":"T31","span":{"begin":523,"end":528},"obj":"Body_part"},{"id":"T32","span":{"begin":536,"end":549},"obj":"Body_part"},{"id":"T33","span":{"begin":633,"end":648},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma62977"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma62983"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma62983"},{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma82746"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T10","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T11","span":{"begin":401,"end":414},"obj":"Body_part"},{"id":"T12","span":{"begin":401,"end":407},"obj":"Body_part"},{"id":"T13","span":{"begin":536,"end":549},"obj":"Body_part"},{"id":"T14","span":{"begin":536,"end":542},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0000347"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0000347"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":344,"end":362},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T31","span":{"begin":33,"end":34},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T32","span":{"begin":281,"end":282},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T33","span":{"begin":303,"end":304},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T34","span":{"begin":337,"end":338},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T35","span":{"begin":369,"end":370},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":510,"end":511},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T37","span":{"begin":591,"end":592},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T22","span":{"begin":149,"end":156},"obj":"Chemical"},{"id":"T23","span":{"begin":166,"end":178},"obj":"Chemical"},{"id":"T25","span":{"begin":371,"end":383},"obj":"Chemical"},{"id":"T26","span":{"begin":633,"end":648},"obj":"Chemical"}],"attributes":[{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_53590"},{"id":"A24","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_61420"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T11","span":{"begin":355,"end":362},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T20","span":{"begin":166,"end":178},"obj":"Chemical"},{"id":"T22","span":{"begin":371,"end":383},"obj":"Chemical"},{"id":"T23","span":{"begin":633,"end":648},"obj":"Chemical"}],"attributes":[{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_53590"},{"id":"A21","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_61420"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T6","span":{"begin":708,"end":716},"obj":"Species"}],"attributes":[{"id":"A6","pred":"ncbi_taxonomy_id","subj":"T6","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T15","span":{"begin":0,"end":439},"obj":"Sentence"},{"id":"T16","span":{"begin":440,"end":550},"obj":"Sentence"},{"id":"T17","span":{"begin":551,"end":807},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T8","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T9","span":{"begin":401,"end":414},"obj":"Body_part"},{"id":"T10","span":{"begin":536,"end":549},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0000347"},{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0000347"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"66","span":{"begin":104,"end":107},"obj":"Gene"},{"id":"70","span":{"begin":344,"end":362},"obj":"Disease"},{"id":"67","span":{"begin":371,"end":383},"obj":"Chemical"},{"id":"68","span":{"begin":523,"end":528},"obj":"Chemical"},{"id":"69","span":{"begin":633,"end":648},"obj":"Chemical"},{"id":"71","span":{"begin":708,"end":716},"obj":"Disease"}],"attributes":[{"id":"A66","pred":"pubann:denotes","subj":"66","obj":"Gene:4099"},{"id":"A70","pred":"pubann:denotes","subj":"70","obj":"MESH:D020271"},{"id":"A67","pred":"pubann:denotes","subj":"67","obj":"MESH:D002241"},{"id":"A68","pred":"pubann:denotes","subj":"68","obj":"MESH:D000073893"},{"id":"A69","pred":"pubann:denotes","subj":"69","obj":"MESH:D011134"},{"id":"A71","pred":"pubann:denotes","subj":"71","obj":"MESH:C000657245"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T33","span":{"begin":104,"end":107},"obj":"Protein"}],"attributes":[{"id":"A33","pred":"uniprot_id","subj":"T33","obj":"https://www.uniprot.org/uniprot/Q567S4"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T25","span":{"begin":108,"end":111},"obj":"Body_part"},{"id":"T26","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T27","span":{"begin":371,"end":383},"obj":"Body_part"},{"id":"T28","span":{"begin":401,"end":414},"obj":"Body_part"},{"id":"T29","span":{"begin":430,"end":438},"obj":"Body_part"},{"id":"T30","span":{"begin":485,"end":493},"obj":"Body_part"},{"id":"T31","span":{"begin":523,"end":528},"obj":"Body_part"},{"id":"T32","span":{"begin":536,"end":549},"obj":"Body_part"},{"id":"T33","span":{"begin":633,"end":648},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma82746"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma62983"},{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma62983"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma62977"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T10","span":{"begin":344,"end":362},"obj":"Disease"},{"id":"T11","span":{"begin":708,"end":716},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-sentences","denotations":[{"id":"T15","span":{"begin":0,"end":439},"obj":"Sentence"},{"id":"T16","span":{"begin":440,"end":550},"obj":"Sentence"},{"id":"T17","span":{"begin":551,"end":807},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}

{"project":"LitCovid-PubTator","denotations":[{"id":"66","span":{"begin":104,"end":107},"obj":"Gene"},{"id":"67","span":{"begin":371,"end":383},"obj":"Chemical"},{"id":"68","span":{"begin":523,"end":528},"obj":"Chemical"},{"id":"69","span":{"begin":633,"end":648},"obj":"Chemical"},{"id":"70","span":{"begin":344,"end":362},"obj":"Disease"},{"id":"71","span":{"begin":708,"end":716},"obj":"Disease"}],"attributes":[{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"Gene:4099"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D002241"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D000073893"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:D011134"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D020271"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors' findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines."}